Evidence map›Paper›PMID 22286212›Full record

ArticleJournal of the National Cancer Institute2012

Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups.

Kevin Y Urayama, Ruth F Jarrett, Henrik Hjalgrim, Arjan Diepstra, Yoichiro Kamatani, Amelie Chabrier, Valerie Gaborieau, Anne Boland, Alexandra Nieters, Nikolaus Becker and 53 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 9 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 9 syntheses or guidelines pooled it, 169 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

63 authors at 4 institutions in 3 countries.

Kevin Y UrayamaGenetics Section, International Agency for Research on Cancer, Lyon, France.
Ruth F Jarrett
Henrik Hjalgrim
Arjan Diepstra
Yoichiro Kamatani
Amelie Chabrier
Valerie Gaborieau
Anne Boland
Alexandra Nieters
Nikolaus Becker
Lenka Foretova
Yolanda Benavente
Marc Maynadié
Anthony Staines
Lesley Shield
Annette Lake
Dorothy Montgomery
Malcolm Taylor
Karin Ekström Smedby
Rose-Marie Amini
Hans-Olov Adami
Bengt Glimelius
Bjarke Feenstra
Ilja M Nolte
Lydia Visser
Gustaaf W van Imhoff
Tracy Lightfoot
Pierluigi Cocco
Lambertus Kiemeney
Sita H Vermeulen
Ivana Holcatova
Lars Vatten
Gary J Macfarlane
Peter Thomson
David I Conway
Simone Benhamou
Antonio Agudo
Claire M Healy
Kim Overvad
Anne Tjønneland
Beatrice Melin
Federico Canzian
Kay-Tee Khaw
Ruth C Travis
Petra H M Peeters
Carlos A González
José Ramón Quirós
María-José Sánchez
José María Huerta
Eva Ardanaz
Miren Dorronsoro
Françoise Clavel-Chapelon
H Bas Bueno-de-Mesquita
Elio Riboli
Eve Roman
Paolo Boffetta
Silvia de Sanjosé
Diana Zelenika
Mads Melbye
Anke van den Berg
Mark Lathrop
Paul Brennan
James D McKay
Radboud University Nijmegen · NLUniversity Hospital Heidelberg · DEHeidelberg University · DECentre International de Recherche sur le Cancer · FR

Funding

Cancer Research UK 14136Medical Research Council G0401527Medical Research Council G1000143Wellcome Trust
6 · The paper itself

Abstract

backgroundAccumulating evidence suggests that risk factors for classical Hodgkin lymphoma (cHL) differ by tumor Epstein-Barr virus (EBV) status. This potential etiological heterogeneity is not recognized in current disease classification.

methodsWe conducted a genome-wide association study of 1200 cHL patients and 6417 control subjects, with validation in an independent replication series, to identify common genetic variants associated with total cHL and subtypes defined by tumor EBV status. Multiple logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) assuming a log-additive genetic model for the variants. All statistical tests were two-sided.

resultsTwo novel loci associated with total cHL irrespective of EBV status were identified in the major histocompatibility complex region; one resides adjacent to MICB (rs2248462: OR = 0.61, 95% CI = 0.53 to 0.69, P = 1.3 × 10(-13)) and the other at HLA-DRA (rs2395185: OR = 0.56, 95% CI = 0.50 to 0.62, P = 8.3 × 10(-25)) with both results confirmed in an independent replication series. Consistent with previous reports, associations were found between EBV-positive cHL and genetic variants within the class I region (rs2734986, HLA-A: OR = 2.45, 95% CI = 2.00 to 3.00, P = 1.2 × 10(-15); rs6904029, HCG9: OR = 0.46, 95% CI = 0.36 to 0.59, P = 5.5 × 10(-10)) and between EBV-negative cHL and rs6903608 within the class II region (rs6903608, HLA-DRA: OR = 2.08, 95% CI = 1.84 to 2.35, P = 6.1 × 10(-31)). The association between rs6903608 and EBV-negative cHL was confined to the nodular sclerosis histological subtype. Evidence for an association between EBV-negative cHL and rs20541 (5q31, IL13: OR = 1.53, 95% CI = 1.32 to 1.76, P = 5.4 x 10(-9)), a variant previously linked to psoriasis and asthma, was observed; however, the evidence for replication was less clear. Notably, one additional psoriasis-associated variant, rs27524 (5q15, ERAP1), showed evidence of an association with cHL in the genome-wide association study (OR = 1.21, 95% CI = 1.10 to 1.33, P = 1.5 × 10(-4)) and replication series (P = .03).

conclusionOverall, these results provide strong evidence that EBV status is an etiologically important classification of cHL and also suggest that some components of the pathological process are common to both EBV-positive and EBV-negative patients.

Indexed as

Herpesvirus 4, HumanAminopeptidasesEpstein-Barr Virus InfectionsGenome-Wide Association StudyHistocompatibility Antigens Class IHLA-DR alpha-ChainsHodgkin DiseaseHumansLogistic ModelsMinor Histocompatibility AntigensOdds RatioRisk FactorsAminopeptidasesERAP1 protein, humanHistocompatibility Antigens Class IHLA-DR alpha-ChainsMICB antigenMinor Histocompatibility Antigens

Identifiers

PMID22286212
PMCPMC3274508
OpenAlexW2170434007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.